Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT Melanoma Vaccine in Advanced Melanoma
NCT03167177Phase 2Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- Dec 2017
- Primary completion
- Jan 2019
- Modality
- Adenoviral Vectors, Fc-Fusion Proteins, Cancer Vaccines
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept, haNK, ETBX-011, ETBX-051, ETBX-061 in melanoma, sponsored by ImmunityBio, Inc.. Planned start Dec 2017; status: withdrawn.
02
Drugs
nogapendekin alfa inbakicepthaNKETBX-011ETBX-051ETBX-061
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03167177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03167177.